Format
Sort by
Items per page

Send to

Choose Destination

Selected items

Items: 20

1.

Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability.

Umar A, Boland CR, Terdiman JP, Syngal S, de la Chapelle A, Rüschoff J, Fishel R, Lindor NM, Burgart LJ, Hamelin R, Hamilton SR, Hiatt RA, Jass J, Lindblom A, Lynch HT, Peltomaki P, Ramsey SD, Rodriguez-Bigas MA, Vasen HF, Hawk ET, Barrett JC, Freedman AN, Srivastava S.

J Natl Cancer Inst. 2004 Feb 18;96(4):261-8.

2.

Identification of Lynch syndrome among patients with colorectal cancer.

Moreira L, Balaguer F, Lindor N, de la Chapelle A, Hampel H, Aaltonen LA, Hopper JL, Le Marchand L, Gallinger S, Newcomb PA, Haile R, Thibodeau SN, Gunawardena S, Jenkins MA, Buchanan DD, Potter JD, Baron JA, Ahnen DJ, Moreno V, Andreu M, Ponz de Leon M, Rustgi AK, Castells A; EPICOLON Consortium..

JAMA. 2012 Oct 17;308(15):1555-65. doi: 10.1001/jama.2012.13088.

3.

Risks of primary extracolonic cancers following colorectal cancer in lynch syndrome.

Win AK, Lindor NM, Young JP, Macrae FA, Young GP, Williamson E, Parry S, Goldblatt J, Lipton L, Winship I, Leggett B, Tucker KM, Giles GG, Buchanan DD, Clendenning M, Rosty C, Arnold J, Levine AJ, Haile RW, Gallinger S, Le Marchand L, Newcomb PA, Hopper JL, Jenkins MA.

J Natl Cancer Inst. 2012 Sep 19;104(18):1363-72. Epub 2012 Aug 28.

4.

Cancer risks associated with germline mutations in MLH1, MSH2, and MSH6 genes in Lynch syndrome.

Bonadona V, Bonaïti B, Olschwang S, Grandjouan S, Huiart L, Longy M, Guimbaud R, Buecher B, Bignon YJ, Caron O, Colas C, Noguès C, Lejeune-Dumoulin S, Olivier-Faivre L, Polycarpe-Osaer F, Nguyen TD, Desseigne F, Saurin JC, Berthet P, Leroux D, Duffour J, Manouvrier S, Frébourg T, Sobol H, Lasset C, Bonaïti-Pellié C; French Cancer Genetics Network..

JAMA. 2011 Jun 8;305(22):2304-10. doi: 10.1001/jama.2011.743.

PMID:
21642682
5.

Revised guidelines for the clinical management of Lynch syndrome (HNPCC): recommendations by a group of European experts.

Vasen HF, Blanco I, Aktan-Collan K, Gopie JP, Alonso A, Aretz S, Bernstein I, Bertario L, Burn J, Capella G, Colas C, Engel C, Frayling IM, Genuardi M, Heinimann K, Hes FJ, Hodgson SV, Karagiannis JA, Lalloo F, Lindblom A, Mecklin JP, Møller P, Myrhoj T, Nagengast FM, Parc Y, Ponz de Leon M, Renkonen-Sinisalo L, Sampson JR, Stormorken A, Sijmons RH, Tejpar S, Thomas HJ, Rahner N, Wijnen JT, Järvinen HJ, Möslein G; Mallorca group..

Gut. 2013 Jun;62(6):812-23. doi: 10.1136/gutjnl-2012-304356. Epub 2013 Feb 13.

6.

Risks of less common cancers in proven mutation carriers with lynch syndrome.

Engel C, Loeffler M, Steinke V, Rahner N, Holinski-Feder E, Dietmaier W, Schackert HK, Goergens H, von Knebel Doeberitz M, Goecke TO, Schmiegel W, Buettner R, Moeslein G, Letteboer TG, Gómez García E, Hes FJ, Hoogerbrugge N, Menko FH, van Os TA, Sijmons RH, Wagner A, Kluijt I, Propping P, Vasen HF.

J Clin Oncol. 2012 Dec 10;30(35):4409-15. doi: 10.1200/JCO.2012.43.2278. Epub 2012 Oct 22.

PMID:
23091106
7.

Hereditary nonpolyposis colorectal cancer (HNPCC)/Lynch syndrome.

Steinke V, Engel C, Büttner R, Schackert HK, Schmiegel WH, Propping P.

Dtsch Arztebl Int. 2013 Jan;110(3):32-8. doi: 10.3238/arztebl.2013.0032. Epub 2013 Jan 18. Review.

8.

Epimutation and cancer: a new carcinogenic mechanism of Lynch syndrome (Review).

Banno K, Kisu I, Yanokura M, Tsuji K, Masuda K, Ueki A, Kobayashi Y, Yamagami W, Nomura H, Tominaga E, Susumu N, Aoki D.

Int J Oncol. 2012 Sep;41(3):793-7. doi: 10.3892/ijo.2012.1528. Epub 2012 Jun 25. Review.

9.

Review of the Lynch syndrome: history, molecular genetics, screening, differential diagnosis, and medicolegal ramifications.

Lynch HT, Lynch PM, Lanspa SJ, Snyder CL, Lynch JF, Boland CR.

Clin Genet. 2009 Jul;76(1):1-18. doi: 10.1111/j.1399-0004.2009.01230.x. Review.

10.

ColoSeq provides comprehensive lynch and polyposis syndrome mutational analysis using massively parallel sequencing.

Pritchard CC, Smith C, Salipante SJ, Lee MK, Thornton AM, Nord AS, Gulden C, Kupfer SS, Swisher EM, Bennett RL, Novetsky AP, Jarvik GP, Olopade OI, Goodfellow PJ, King MC, Tait JF, Walsh T.

J Mol Diagn. 2012 Jul;14(4):357-66. doi: 10.1016/j.jmoldx.2012.03.002. Epub 2012 May 30.

11.

Risks of colorectal and other cancers after endometrial cancer for women with Lynch syndrome.

Win AK, Lindor NM, Winship I, Tucker KM, Buchanan DD, Young JP, Rosty C, Leggett B, Giles GG, Goldblatt J, Macrae FA, Parry S, Kalady MF, Baron JA, Ahnen DJ, Marchand LL, Gallinger S, Haile RW, Newcomb PA, Hopper JL, Jenkins MA.

J Natl Cancer Inst. 2013 Feb 20;105(4):274-9. doi: 10.1093/jnci/djs525. Epub 2013 Feb 5.

12.

Endometrial cancer and Lynch syndrome: clinical and pathologic considerations.

Meyer LA, Broaddus RR, Lu KH.

Cancer Control. 2009 Jan;16(1):14-22. Review.

13.

Unusual DNA mismatch repair-deficient tumors in Lynch syndrome: a report of new cases and review of the literature.

Karamurzin Y, Zeng Z, Stadler ZK, Zhang L, Ouansafi I, Al-Ahmadie HA, Sempoux C, Saltz LB, Soslow RA, O'Reilly EM, Paty PB, Coit DG, Shia J, Klimstra DS.

Hum Pathol. 2012 Oct;43(10):1677-87. doi: 10.1016/j.humpath.2011.12.012. Epub 2012 Apr 17. Review.

PMID:
22516243
14.

Lynch syndrome and MYH-associated polyposis: review and testing strategy.

Goodenberger M, Lindor NM.

J Clin Gastroenterol. 2011 Jul;45(6):488-500. doi: 10.1097/MCG.0b013e318206489c. Review.

PMID:
21325953
15.

Risks of Lynch syndrome cancers for MSH6 mutation carriers.

Baglietto L, Lindor NM, Dowty JG, White DM, Wagner A, Gomez Garcia EB, Vriends AH; Dutch Lynch Syndrome Study Group., Cartwright NR, Barnetson RA, Farrington SM, Tenesa A, Hampel H, Buchanan D, Arnold S, Young J, Walsh MD, Jass J, Macrae F, Antill Y, Winship IM, Giles GG, Goldblatt J, Parry S, Suthers G, Leggett B, Butz M, Aronson M, Poynter JN, Baron JA, Le Marchand L, Haile R, Gallinger S, Hopper JL, Potter J, de la Chapelle A, Vasen HF, Dunlop MG, Thibodeau SN, Jenkins MA.

J Natl Cancer Inst. 2010 Feb 3;102(3):193-201. doi: 10.1093/jnci/djp473. Epub 2009 Dec 22.

16.

Strategies to identify the Lynch syndrome among patients with colorectal cancer: a cost-effectiveness analysis.

Ladabaum U, Wang G, Terdiman J, Blanco A, Kuppermann M, Boland CR, Ford J, Elkin E, Phillips KA.

Ann Intern Med. 2011 Jul 19;155(2):69-79. doi: 10.7326/0003-4819-155-2-201107190-00002.

17.

Lynch syndrome: clinical, pathological, and genetic insights.

Schneider R, Schneider C, Kloor M, Fürst A, Möslein G.

Langenbecks Arch Surg. 2012 Apr;397(4):513-25. doi: 10.1007/s00423-012-0918-8. Epub 2012 Feb 24. Review.

PMID:
22362054
18.

The clinical phenotype of Lynch syndrome due to germ-line PMS2 mutations.

Senter L, Clendenning M, Sotamaa K, Hampel H, Green J, Potter JD, Lindblom A, Lagerstedt K, Thibodeau SN, Lindor NM, Young J, Winship I, Dowty JG, White DM, Hopper JL, Baglietto L, Jenkins MA, de la Chapelle A.

Gastroenterology. 2008 Aug;135(2):419-28. doi: 10.1053/j.gastro.2008.04.026. Epub 2008 May 2.

19.

Microsatellite instability and DNA mismatch repair protein deficiency in Lynch syndrome colorectal polyps.

Yurgelun MB, Goel A, Hornick JL, Sen A, Turgeon DK, Ruffin MT 4th, Marcon NE, Baron JA, Bresalier RS, Syngal S, Brenner DE, Boland CR, Stoffel EM.

Cancer Prev Res (Phila). 2012 Apr;5(4):574-82. doi: 10.1158/1940-6207.CAPR-11-0519. Epub 2012 Jan 18.

20.

Is breast cancer a part of Lynch syndrome?

Ford JM.

Breast Cancer Res. 2012 Aug 22;14(4):110. doi: 10.1186/bcr3241.

Supplemental Content

Support Center